The prognostic significance of elevations in creatine kinase-MB and troponin T (cTnT), which have been conventionally measured 6 to 8 h after percutaneous coronary intervention (PCI), has been established. However, the time to peak biomarker appearance in the circulation has not been defined and is the purpose of this pilot study. Key words: biomarkers; coronary artery disease; creatine kinase-MB; peak values; percutaneous coronary intervention; troponin T Abbreviations: CK ϭ creatine kinase; cTnT ϭ creatione kinase-MB and troponin T; PCI ϭ percutaneous coronary intervention; PTCA ϭ percutaneous transluminal coronary angioplasty
T he prognostic importance of elevations in biomarkers such as total creatine kinase (CK), CK-MB, and troponin T and I after percutaneous coronary intervention (PCI) is well accepted. [1] [2] [3] [4] [5] [6] [7] [8] [9] The measurement of CK-MB has for years been the mainstay for determining prognosis after PCI. CK-MB and troponin T (cTnT) or CK-MB and troponin I are more sensitive and specific markers of myocardial injury and are now preferred. 2, 10, 11 It has been conventional to monitor serum biomarker levels 6 to 8 h following the completion of coronary interventions, and these values have usually been used to attempt to define prognosis. The implicit assumption has been that by these times peak or near-peak values have been attained. However, the relationship between revascularization procedures and the time to biomarker release and appearance in the blood and the time to peak levels has never been rigorously defined. CK-MB or troponin T values generally peak approximately 18 to 24 h after the onset of a myocardial infarction. However, acute reperfusion shortens the time to peak protein concentration in the blood, and increases the absolute peak and the rate of decline in the circulation. Conversely, reduced blood flow may delay the appearance of markers in the blood. Therefore, the timing of surveillance monitoring to detect peak biomarker levels may be critical following procedures where occlusion, reperfusion and, at times, reduced blood flow can occur. The purpose of this pilot study was to measure levels of troponin T and CK-MB at predetermined time intervals following PCI to establish the timing of peak biomarker concentration. By design, the study attempted to include an equal number of patients undergoing complex procedures who received IIb/IIIa inhibitor therapy and uncomplicated procedures where patients did not receive such therapy to capture the broadest range of patients possible.
Materials and Methods
Troponin T and CK-MB were measured in a nonrandomized, nonconsecutive cohort of patients (n ϭ 57) during the period of September to November 2000. Patients were referred for elective coronary angiography and PCI with the diagnosis of progressive symptomatic coronary artery disease. Thrombolysis in Myocardial Infarction (TIMI) grade 3 coronary artery blood flow was established in all patients. Troponin T and CK-MB were measured at 2 h, 4 h, 8 h, and 12 to 20 h (mean Ϯ SEM, 17.9 Ϯ 0.46 h) postprocedure.
Abciximab was used in conjunction with the intervention when deemed clinically indicated. The dose was 0.25 mg/kg IV followed by 0.125 g/kg/min for 12 h after PCI. All patients received aspirin (325 mg) before the intervention, and patients receiving stent implantation received clopidogrel (375 mg) prior to stent placement. Subsequently, peak biomarker levels were determined at each time interval. Any increase in cTnT Ն 0.03 ng/mL (the value at which the coefficient of variability of the assay is Յ 10%) 12 and CK-MB Ն 6.2 ng/mL was defined as a clinically significant elevation. Troponin T assays were performed using highly sensitive and precise third-generation assay (Elecsys; Roche Diagnostics; Indianapolis, IN). The cTnT assay has a coefficient of variability of 10% at a value of 0.035 ng/mL and 20% at 0.015 ng/mL. The limit of detection is Յ 0.01 ng/mL. 
Results
The baseline clinical characteristics of the 57 patients included in the study are shown in Table 1 . The procedural treatment profile of patients undergoing PCI is shown in Table 2 . Fifty-six percent of these patients received IIb/IIIa inhibitor therapy (abciximab) in association with the procedure, and 39% were stented without IIb/IIIa inhibitor. Four of the 57 patients (7%) were treated with percutaneous transluminal coronary angioplasty (PTCA)-only therapy; of these, 1 patient received abciximab. 57 patients demonstrated elevations in CK-MB, with all patients receiving stents and 86% treated with abciximab. Table 4 shows the timing of peak cTnT and CK-MB elevations after intervention. Postprocedure cTnT elevations were detected in 42% of patients. Of these, no patients demonstrated peak cTnT levels by 2 h after PCI. One of the 24 patients (4%) had peak cTnT elevation at 4 h after PCI (3.14 ng/mL), 3 of 24 patients (12.5%) had peak cTnT at 8 h after PCI (1.73 Ϯ 0.48 ng/mL), and 20 of 24 patients (83%) had peak cTnT at 12 to 20 h (mean, 18 Ϯ 0.5 h) after PCI (0.22 Ϯ 0.06 ng/mL). The differences in cTnT levels late (12 to 20 h) were often substantial (range, 0.02 to 1.14 ng/mL; mean difference, Ͼ 0.1 ng/mL). The majority (18 of 24 patients) with cTnT elevations were receiving abciximab. Of the 33 patients who underwent PCI without a postprocedure cTnT elevation, only 10 patients received abciximab.
Elevations in CK-MB mass after PCI occurred in only 14 of 57 patients (25%). Of these, 3 of 14 patients (21%) demonstrated peak CK-MB at 2 h after PCI (18.5 Ϯ 7.9 ng/mL), and the remainder during the 12-to 20-h intervals (11 of 14 patients, 79%; 20.2 Ϯ 4.4 ng/mL). No peak CK-MB levels were detected at 4 h or 8 h after PCI. Thirteen of 14 patients with CK-MB elevations also had elevations of cTnT, with 12 of 14 occurring during the 12-to 20-h interval. Similar to the patients with cTnT elevations, the majority (12 of 14 patients) with CK-MB elevations received abciximab. Only 2 of 14 patients underwent stent therapy without adjunctive IIb/IIIa therapy. Of the 43 patients without elevations in CK-MB after PCI, 20 patients (46%) were receiving abciximab.
Five of the 57 patients undergoing PCI had elevations in baseline cTnT levels. In retrospect, it is likely from the cardiac enzyme findings that these patients experienced some degree of cardiac injury in the 72 to 96 h before the procedure. When these baseline elevations are excluded from the study ( Table 5 ), 100% of the cTnT elevations are recorded in the 12-to 20-h interval. Seventy-nine percent of these patients received abciximab. Similarly, 92% of the CK-MB elevations were observed in the 12-to 20-h time interval after PCI, with only one patient demonstrating a peak level at the 2-h interval.
Data were also analyzed for other cut-points for cTnT (Ն 0.01 ng/mL and Ն 0.10 ng/mL) and similar findings were demonstrated when baseline elevations were excluded. Eighty percent and 92% of peak levels for cTnT and CK-MB, respectively, were recorded in the 12-to 20-h interval when cTnT cut-point was Յ 0.01 ng/mL, and 100% and 92%, respectively, when the cut-point was Յ 0.10 ng/mL.
Discussion
The results of our pilot study indicate that the clinical practice convention of surveillance monitoring for elevations in cTnT and CK-MB at 6 to 8 h following elective catheter-based coronary artery interventions will not detect peak elevations in the majority of patients. This may be a reason for the variability in results reported across studies.
As in previous reports, [13] [14] [15] [16] [17] [18] myocardial injury was diagnosed in more patients based on cTnT elevations (42% of postprocedural patients) than CK-MB elevations (25% of patients). The majority of elevations of both biomarkers (83% for cTnT; 79% for CK-MB) were detected late (12 to 20 h following PCI). The absolute magnitude of late cTnT elevations was lower than when peak values were present at 4 h and 8 h (0.80 ng/mL and 1.07 ng/mL, respectively, vs 0.21 ng/mL; p Ͻ 0.05). If prognosis is predicted only on peak levels, then the findings of elevations at 4-h and 8-h peaks would suggest a poorer prognosis for those groups than those with later elevations which was the majority of patients. In our study, these earlier elevations occurred in patients with baseline elevations of cTnT. When patients with these baseline elevations are removed from the analysis, all post-PCI cTnT elevations occurred in the 12-to 20-h interval. Since most (79%) of the patients with cTnT elevations in the 12-to 20-h interval group had received IIb/IIIa therapy in association with the procedure, the lower cTnT elevations might be explained by a beneficial effect of abciximab. 19 -22 However, in the majority of patients with elevations at 8 h (two of three patients) where we also observed higher absolute cTnT levels, they also received abciximab. Additionally, 30% of patients who did not demonstrate any cTnT elevations received abciximab. Therefore, it would be difficult to determine if IIb/IIIa inhibitor therapy had a substantial impact on the outcome of myocardial injury following PCI in this cohort. For this cohort, such a comparison would be inappropriate since the study was not randomized and the patients undergoing more complex PCI were the ones who received IIb/IIIa inhibitor therapy. Factors such as complications related to the procedure, balloon inflation times, the rate of distal perfusion leading to biomarker washout, the complexity of the coronary artery anatomy, and side branch occlusion after stent placement may also have a role in explaining the absolute magnitude and time to peak cTnT elevation. Substantially fewer positive CK-MB measurements were demonstrated after PCI. However, the principles that were operative for cTnT were also operative for CK-MB. The majority (79%) of elevations were observed at 12 to 20 h. Only three patients had elevations in CK-MB earlier than this time interval, and these occurred at 2 h after the procedure. The majority (12 of 14 patients; 86%) with CK-MB elevations also received abciximab. In the group of patients without evidence of CK-MB elevations (a less complex group), only 46% (20 of 43 patients) were treated with abciximab.
Various formats for serial blood sampling to detect elevations in cardiac biomarkers have been reported in conjunction with clinical trials of periprocedure therapies. 1, 3, 5, [23] [24] [25] These have ranged from immediate through 48 to 72 h, but generally entail serial sampling ranging over the intervals of Ͻ 1 h to 4 h, 6 h, 8 h, 12 h, 18 h, and 24 h after the onset of symptoms or postprocedure. No systematic analysis has provided guidelines for optimal monitoring time intervals to capture peak cTnT or CK-MB levels. By convention and also by European Society of Cardiology/American College of Cardiology consensus document recommendation, 26 the intervals of 6 to 9 h and 24 h after PCI have generally been selected for blood sampling. Recommendations have also been made to obtain routine measurements at baseline and 8 h and 16 h after PCI. 3 Bertinchant et al 27 reported a time to median peak cTnT of 21 h following uncomplicated PTCA. The findings of our study and the data from Bertinchant et al 27 suggest that a longer time interval than the more conventional 6-to 8-h interval for surveillance biomarker monitoring after PCI should be adopted, and a standardized approach to surveillance monitoring employed in clinical research if peak values are being used to define prognosis.
However, the range of timing of peak elevations for both cTnT and CK-MB among the time interval groups following uncomplicated procedures suggests that perhaps the pattern may be as important as the peak values. Patients receiving abciximab who had more complex procedures elaborated biomarkers later and had lower peak values. If this is universally the case, then peak values that occur early may be due to better reperfusion and may be of less prog- nostic significance despite a greater magnitude. The timing of peak elevations appears also to be influenced by baseline values. Therefore, early elevations (2 to 10 h) may reflect the combined effects of the intrinsic disease presentation with cardiac injury and the intervention itself. Since the release rate (the amount of marker depleted from the myocardium that appears in the plasma) is flow dependent, 28 especially for CK-MB, early marker elevations may be of less significance than later, perhaps even lower, marker elevations. Myocardial release rates of biomarkers may also vary under different clinical conditions. Release rates associated with minimal myocardial injury after PCI (late peak) may be quite different from the release rates under conditions of the more profound injury of acute myocardial infarction and reperfusion therapy (early peak). Even analyses such as the use of the area under the time-concentration curve may not correct for such differences. It may be that the type of analysis done in the Troponin in Planned PTCA/ Stent Implantation With or Without Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Tirofiban trial 29 is necessary to understand and fully utilize the prognostic significance of this biomarker release in this setting; in that study, peak levels were often not observed until 48 h after procedure.
In conclusion, although cTnT elevations are more likely to occur after PCI than CK-MB elevations, both markers demonstrate a longer time to peak value than generally anticipated in clinical practice. Thus, longer time intervals should be used for surveillance monitoring postprocedure if peak values are to be accurately determined for prognosis. Only then will accurate analyses based on peak values be achievable. Studies then should be able to clarify the magnitude of these effects and whether peak elevations alone provide the best prognostic information and/or the best way to assess the effects of adjunctive therapies.
